Cancer nanomedicines: So many papers and so few drugs

This review identifies a timeline to nanomedicine anticancer drug approval using the business model of inventors, innovators and imitators. By evaluating the publication record of nanomedicine cancer therapeutics we identified a trend of very few publications prior to FDA approval. We first enumerat...

Full description

Saved in:
Bibliographic Details
Published inAdvanced drug delivery reviews Vol. 65; no. 1; pp. 80 - 88
Main Authors Venditto, Vincent J., Szoka, Francis C.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.01.2013
Subjects
Online AccessGet full text

Cover

Loading…